Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease

Next Previous
Trial Profile

A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 04 Sep 2020 Results of post hoc analysis from NCT02298829, NCT01221597, NCT01221623, NCT01243411 and NCT01685437 determoning the long-term (5 year) efficacy and safety profile of CCH in men subgrouped by the degree of penile plaque calcification prior to treatment, published in the Urology
  • 19 May 2015 Results presented at the American Urological Association (AUA) at its 110th Annual Scientific Meeting, as reported by Endo Pharmaceuticals media release.
  • 30 Jan 2015 According to a Swedish Orphan Biovitrum AB media release, the EU Commission has approved Xiapex for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top